Publications by authors named "David Fairman"

Claim this Profile
S
Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of GSK3772847 in healthy participants.
Eleni Pefani, Sally Stone, Chang-Qing Zhu, Carol Nunn, David Fairman

Pharmacol Res Perspect· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial.
Chika Akinseye, Courtney Crim, Amy Newlands, David Fairman

PLoS One· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best Practices in mAb and Soluble Target Assay Selection for Quantitative Modelling and Qualitative Interpretation.
David Fairman, Huaping Tang

AAPS J· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling" [International Journal of Cardiology 167 (2013) 2630-2637].
Baktybek Kojonazarov, Akylbek Sydykov, Soni Savai Pullamsetti, Himal Luitel, Bhola K Dahal, David Fairman

Int J Cardiol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How translational modeling in oncology needs to get the mechanism just right.
James W T Yates, David A Fairman

Clin Transl Sci· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Free Drug Theory - No Longer Just a Hypothesis?
Scott G Summerfield, James W T Yates, David A Fairman

Pharm Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor.
Toby M Maher, Juliet K Simpson, Joanna C Porter, Frederick J Wilson, Robert Chan, David Fairman

Respir Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment.
Matthieu Chodorge, Anthony J Celeste, Joseph Grimsby, Anish Konkar, Pia Davidsson, David Fairman

Sci Rep· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants.
Charlotte H Maden, David Fairman, Michelle Chalker, Maria J Costa, William A Fahy

Eur J Clin Pharmacol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.
Akram Khan, Cody Benthin, Brian Zeno, Timothy E Albertson, John Boyd, David A Fairman

Crit Care· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling.
Baktybek Kojonazarov, Akylbek Sydykov, Soni Savai Pullamsetti, Himal Luitel, Bhola K Dahal, David Fairman

Int J Cardiol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of leukotriene and 5oxoETE synthesis and the effect of 5-lipoxygenase inhibitors: a mathematical modeling approach.
Tatiana A Karelina, Kirill V Zhudenkov, Oleg O Demin, Dmitry V Svetlichny, Balaji Agoram, David Fairman

BMC Syst Biol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.
David S Millan, Mark E Bunnage, Jane L Burrows, Kenneth J Butcher, Peter G Dodd, David A Fairman

J Med Chem· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acidic triazoles as soluble guanylate cyclase stimulators.
Lee R Roberts, Paul A Bradley, Mark E Bunnage, Katherine S England, David Fairman

Bioorg Med Chem Lett· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.
Paul A Glossop, Christine A L Watson, David A Price, Mark E Bunnage, Donald S Middleton, David A Fairman

J Med Chem· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD.
Lyn H Jones, Helen Baldock, Mark E Bunnage, Jane Burrows, Nick Clarke, David Fairman

Bioorg Med Chem Lett· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small, non-peptide C5a receptor antagonists: part 2.
Julian Blagg, Charles Mowbray, David Pryde, Gary Salmon, David Fairman

Bioorg Med Chem Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small, non-peptide C5a receptor antagonists: part 1.
Julian Blagg, Charles Mowbray, David C Pryde, Gary Salmon, Esther Schmid, David Fairman

Bioorg Med Chem Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Normalizing effective conflict management through academic curriculum integration: the example of workable peace.
Stacie Nicole Smith, David Fairman

New Dir Youth Dev· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
Alan MacInnes, David A Fairman, Peter Binding, Jo ann Rhodes, Michael J Wyatt

Circ Res· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis